MHE October 2025
Site neutrality payment, innovations in care delivery and value-based pricing of drugs could at least help to moderate the huge growth in expenditures.
Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy product.
At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of artificial intelligence. Some leaders caution about using it too widely, too fast.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
California PBM Law is a Starting Point for Real Transparency
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
WHO Global Report on Antimicrobial Resistance Sheds Light on Growing Threat
4
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
5
